EUVIMEDEUVIMED entdecken
Crossref

1658-P: Characterization and Preclinical Efficacy of a Novel Unimolecular Amylin and GLP-1 Receptor Dual Agonist, VRB-104

MARTIJN FENAUX, JAMES FRANCIS, CATHERINE L. JONES, SCOTT J. SHARP, HAIXIA ZOU, YAN LI, XINLE WU, RUI ZHU, SUJUAN HAO, ZHAOYING LI, YAN WANG, JINYI ZHAO und 1 weitere

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1658-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von MARTIJN FENAUX und 12 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: GLP-1 and amylin are peptide hormones that independently reduce appetite, slow gastric emptying, and decrease glucagon release. Combination of GLP-1 and amylin receptor agonists demonstrates greater weight loss and glycemic control than either agent alone. Here we assessed the in vitro potency, in vivo efficacy, and pharmacokinetics (PK) of VRB-104, a novel unimolecular amylin & GLP-1 receptor dual agonist.

Methods

VRB-104 was tested in reporter cell lines overexpressing human GLP-1 receptor (hGLP-1R) or amylin receptor (hAMY3R); amycretin was used as a comparator. VRB-104 was administered via daily subcutaneous injection in a diet-induced obese (DIO) rat model for 14 days, with body weight and food intake recorded daily. Single dose subcutaneous PK studies with VRB-104 were performed in rats, mini-pigs, and cynomolgus monkeys.

Results

In cell culture, VRB-104 showed 3-fold increased potency on the hAMY3R compared to amycretin, while showing 6-fold reduced potency on the GLP-1R compared to amycretin. In the DIO rat model, VRB-104 dosed daily for 14 days induced a -14% body weight loss from baseline compared to +1% weight gain for vehicle. Single subcutaneous dose PK studies showed a half-life of 12.3 h in rats, 67.9 h in minipigs, and 33.7 h in cynomolgus monkeys.

Conclusion

VRB-104 is a novel unimolecular amylin & GLP-1 receptor dual agonist, with selectivity for hAMY3R over GLP-1R. These data support the continued development of VRB-104 for the treatment of obesity and type 2 diabetes. Disclosure M. Fenaux: None. J. Francis: Employee; Current; Verdiva Bio. C.L. Jones: Employee; Current; Verdiva Bio. S.J. Sharp: Research Support; Current; Verdiva Bio. H. Zou: Employee; Current; Sciwind Biosciences. Y. Li: Employee; Current; Sciwind Biosciences. X. Wu: Employee; Current; Sciwind Biosciences. R. Zhu: Employee; Current; Sciwind Biosciences. S. Hao: Employee; Current; Sciwind Biosciences. Z. Li: Employee; Current; Sciwind Biosciences. Y. Wang: Employee; Current; Sciwind Biosciences. J. Zhao: Employee; Current; Sciwind Biosciences. W. Zhong: None.

Zitieren

APA

FENAUX, M., FRANCIS, J., JONES, C. L., SHARP, S. J., ZOU, H., LI, Y., WU, X., ZHU, R., HAO, S., LI, Z., WANG, Y., ZHAO, J., & ZHONG, W. (2026). 1658-P: Characterization and Preclinical Efficacy of a Novel Unimolecular Amylin and GLP-1 Receptor Dual Agonist, VRB-104. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1658-p

Vancouver

FENAUX M, FRANCIS J, JONES CL, SHARP SJ, ZOU H, LI Y, et al. 1658-P: Characterization and Preclinical Efficacy of a Novel Unimolecular Amylin and GLP-1 Receptor Dual Agonist, VRB-104. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1658-p

BibTeX
@article{FENAUX2026,
  author = {FENAUX, MARTIJN and FRANCIS, JAMES and JONES, CATHERINE L. and SHARP, SCOTT J. and ZOU, HAIXIA and LI, YAN and WU, XINLE and ZHU, RUI and HAO, SUJUAN and LI, ZHAOYING and WANG, YAN and ZHAO, JINYI and ZHONG, WEIDONG},
  title = {1658-P: Characterization and Preclinical Efficacy of a Novel Unimolecular Amylin and GLP-1 Receptor Dual Agonist, VRB-104},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1658-p}
}
Kostenlos starten →